Sermorelin

What Is Sermorelin?

Sermorelin acetate is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of the 44-amino acid human growth hormone-releasing hormone (GHRH). It is the shortest fully functional fragment of endogenous GHRH — meaning it retains complete biological activity despite being only two-thirds the length of the native hormone. Molecular weight: ~3,357.9 Da. CAS: 86168-78-7. Developed by Serono Laboratories (now EMD Serono).

Sermorelin occupies a unique position in the peptide landscape: it is the only GH secretagogue that was previously FDA-approved and that remains in Category 1 — meaning it can still be legally compounded. This combination of prior regulatory approval, documented safety data, and current legal availability makes it the most defensible option in the growth hormone secretagogue class.

How It Works

Sermorelin binds to and activates GHRH receptors on somatotroph cells of the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous human growth hormone (hGH). This mechanism differs fundamentally from exogenous recombinant hGH (rhGH) injection in several clinically relevant ways:

Preserved feedback loops: Sermorelin’s effects are regulated by somatostatin, the inhibitory hormone that governs GH release. This means the pituitary’s natural brake system remains functional, making GH overdose through sermorelin essentially impossible — unlike direct rhGH injection, which bypasses this safety mechanism entirely.

Pulsatile release pattern: Rather than the constant, unphysiological “square wave” of GH levels produced by rhGH injections, sermorelin promotes episodic GH release that mirrors the body’s natural circadian pattern — with the majority of release occurring during sleep.

Pituitary maintenance: Research suggests sermorelin stimulates GH gene transcription and may support pituitary somatotroph function over time (Walker RF, Clin Interv Aging, 2006;1(4):307–308), potentially slowing the age-related decline in GH secretory capacity rather than simply replacing the downstream hormone.

Subcutaneous bioavailability: Following a single 1.4 mg subcutaneous dose, sermorelin exhibited a mean elimination half-life of approximately 8 minutes in healthy subjects. The brief half-life necessitates once-daily or twice-daily dosing, typically administered before bedtime to align with natural nocturnal GH pulses.

What the Research Actually Shows

FDA Approval History (This Matters)

Sermorelin has a documented regulatory history that no other grey-market GH secretagogue can claim:

• December 1990: FDA approved sermorelin injection (0.05 mg base/amp) under NDA 19-863 as a diagnostic agent for assessing pituitary GH secretion capacity.
• September 1997: FDA approved sermorelin acetate injection (0.5 mg and 1.0 mg base/vial) under NDA 20-443 as Geref for the treatment of idiopathic growth hormone deficiency in children with growth failure.
• 2008: EMD Serono voluntarily discontinued production for commercial reasons — rhGH had captured the pediatric GHD market, and sermorelin’s niche was too small to justify manufacturing costs.
• March 2013: FDA formally determined under § 314.161 that Geref “was not withdrawn from sale for reasons of safety or effectiveness.” This determination is documented in the Federal Register (78 FR 14095).

This last point is critical: the FDA explicitly confirmed that sermorelin’s removal from market was a business decision, not a safety signal. This is why sermorelin remains in Category 1 and can be legally compounded today.

Clinical Studies in Adults

While sermorelin’s FDA approval was for pediatric GHD, several clinical studies have evaluated its effects in adults:

Corpas et al. (J Clin Endocrinol Metab, 1992;75(2):530–535): Evaluated sermorelin in 9 young men (22–33) and 10 elderly men (60–78). Twice-daily injections of low (0.5 mg) or high (1 mg) dose sermorelin for 14 days elevated mean 24-hour GH, peak GH amplitude, and IGF-1 levels in elderly men in a dose-response pattern, approaching levels seen in younger subjects. IGF-1 elevations persisted above baseline even 2 weeks after stopping sermorelin. Serum testosterone levels positively correlated with 24-hour mean GH levels in the elderly men, though this was not statistically significant.

Vittone et al. (J Gerontol A Biol Sci Med Sci, 1997;52(5):M281–M286): 11 healthy elderly men (64–76) received 2 mg subcutaneous sermorelin nightly for 6 weeks. Demonstrated increased GH pulse amplitude without altering pulse frequency.

Khorram et al. (Clin Endocrinol, 1997;47(3):327–336): Examined effects of sermorelin in healthy elderly men and women over an extended period. Reported improvements in body composition including increased lean mass.

Walker RF (Clin Interv Aging, 2006;1(4):307–308): Review arguing sermorelin’s stimulation of endogenous GH through preserved pituitary feedback loops represents a safer approach to age-related GH decline than rhGH, with the added theoretical benefit of slowing pituitary somatotroph deterioration.

Sigalos JT et al. (World J Mens Health, 2020;38(2):151–164): Reviewed sermorelin and other GH secretagogues in the context of hypogonadal males and body composition management. Found that sermorelin uniquely stimulated both FSH and LH release in addition to GH, suggesting potential complementary effects on the HPG axis.

What’s Missing

Despite its relative evidence advantage, critical gaps remain:

• No large, randomized, placebo-controlled trial in adults for body composition, muscle growth, or anti-aging endpoints
• No long-term safety data beyond a few months of administration in adult populations
• No head-to-head comparison with other GH secretagogues (CJC-1295, ipamorelin) in published literature
• Most adult studies are from the 1990s — the evidence base has not been substantially updated
• Tachyphylaxis concerns: Some clinical observations suggest that sermorelin’s GH-stimulating effects may diminish over time with continuous use, though this is not definitively established

Safety Profile

Sermorelin’s safety profile is better documented than most peptides due to its FDA approval history:

From clinical trials and post-marketing data: The most commonly reported adverse effects are injection site reactions (pain, redness, swelling), facial flushing, headache, dizziness, and transient drowsiness. Less common: arthralgia, erythema, myalgia, peripheral edema.

Theoretical advantages over rhGH: Because sermorelin works through the body’s own feedback systems, the risks of GH excess — including insulin resistance, joint problems, carpal tunnel syndrome, and potential tumor promotion — are substantially reduced compared to direct GH injection. Somatostatin acts as a physiological ceiling on GH output.

Unknowns: Long-term effects of sustained pituitary stimulation in adults have not been studied. Whether chronic sermorelin use could desensitize pituitary GHRH receptors (tachyphylaxis) remains an open question. No systematic cancer-risk evaluation has been conducted for long-term adult use.

Contraindications: Patients with known hypothyroidism should be cautioned — thyroid hormone is necessary for GH secretion, and untreated hypothyroidism may blunt sermorelin’s effects. Active malignancy is a theoretical contraindication due to GH/IGF-1’s role in cell proliferation, though this concern applies to all GH-stimulating therapies.

Legal and Regulatory Status

FDA: Category 1 — sermorelin can be legally compounded by 503A and 503B pharmacies. This is the single most important regulatory distinction between sermorelin and every other popular GH secretagogue. It is no longer FDA-approved as a commercial product (Geref was discontinued in 2008), but the FDA’s 2013 determination that it was not withdrawn for safety reasons preserves its compounding eligibility.

WADA: Prohibited under S2.2.4 (Growth Hormone Releasing Factors) as a GHRH analogue. Athletes should be aware that sermorelin will trigger anti-doping violations regardless of prescription status. USADA explicitly notes that a TUE for sermorelin is “highly unlikely” as it is not a first-line treatment for GHD.

DEA: Sermorelin is not a controlled substance. No DEA scheduling applies.

Off-label prescribing: Unlike rhGH, which has legal restrictions on its clinical use for certain applications, off-label prescribing of sermorelin by licensed physicians is not prohibited by federal law.

Common Vendor Claims vs. Reality

What vendors/clinics say	What the evidence shows
”FDA-approved”	Misleading — was FDA-approved (1990/1997), discontinued 2008. Not currently FDA-approved for any indication.
”Boosts testosterone”	Small studies show correlation between GH levels and testosterone in elderly men, but the effect was not statistically significant. Sermorelin does not reliably increase testosterone.
”Builds muscle / burns fat”	Small studies show favorable body composition trends (increased lean mass, decreased fat mass), but no large RCT with muscle growth as a primary endpoint exists.
”Anti-aging”	Mechanism is plausible (restoring youthful GH patterns), but no trial has demonstrated reversal of aging biomarkers with clinical significance.
”Safer than HGH”	Largely supported — the preserved feedback mechanism is a genuine safety advantage. But “safer than HGH” and “proven safe for long-term use” are different claims.
”No side effects”	Side effects are mild and uncommon, but they exist (injection site reactions, flushing, headache).

The Bottom Line

Sermorelin is the most legally and scientifically defensible GH secretagogue currently available. Its prior FDA approval history, Category 1 compounding status, and preserved physiological feedback mechanisms give it meaningful advantages over CJC-1295 and ipamorelin — both of which are Category 2 prohibited and lack any history of FDA approval. For anyone interested in GH secretagogue therapy, sermorelin obtained through a licensed compounding pharmacy with a legitimate prescription represents the lowest-risk option in this class.

That said, “lowest risk” is not “no risk” and “most evidence” is still not “strong evidence.” The adult clinical studies are small, dated, and focused on short-term hormonal endpoints. If you’re considering sermorelin for muscle growth or anti-aging, you should understand that you’re relying on plausible mechanism and small pilot data — not the kind of robust Phase III evidence that exists for, say, semaglutide’s metabolic effects. Work with a physician who can monitor IGF-1 levels and adjust dosing accordingly.

---

This profile will be updated as new research becomes available. Last reviewed: February 25, 2026.